Filtered By:
Drug: Temodar
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 1478 results found since Jan 2013.
Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma
CONCLUSIONS: These results establish LP-184 as a promising chemotherapeutic for GBM with enhanced efficacy in intrinsic or spironolactone-induced TC-NER deficient tumors.PMID:37494541 | DOI:10.1158/1078-0432.CCR-23-0673
Source: Clinical Cancer Research - July 26, 2023 Category: Cancer & Oncology Authors: Bachchu Lal Aditya Kulkarni Joseph McDermott Rana Rais Jesse Alt Ying Wu Hernando Lopez-Bertoni Sophie Sall Umesh Kathad Jianli Zhou Barbara S Slusher Kishor Bhatia John Laterra Source Type: research
The role of PKN1 in glioma pathogenesis and the antiglioma effect of raloxifene targeting PKN1
J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17860. Online ahead of print.ABSTRACTPKN1 (protein kinase N1), a serine/threonine protein kinase family member, is associated with various cancers. However, the role of PKN1 in gliomas has rarely been studied. We suggest that PKN1 expression in glioma specimens is considerably upregulated and positively correlates with the histopathological grading of gliomas. Knocking down PKN1 expression in glioblastoma (GBM) cells inhibits GBM cell proliferation, invasion and migration and promotes apoptosis. In addition, yes-associated protein (YAP) expression, an essential effector of the...
Source: Molecular Medicine - July 22, 2023 Category: Molecular Biology Authors: Yubing Hao Zelin Li Anling Zhang Li Sun Guangxiu Wang Hu Wang Zhifan Jia Source Type: research
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
CONCLUSIONS: Anlotinib combined with temozolomide is efficacious and tolerated in recurrent GBM patients.PMID:37477938 | DOI:10.1158/1078-0432.CCR-23-0388
Source: Clinical Cancer Research - July 21, 2023 Category: Cancer & Oncology Authors: Qingsheng Xu Kaiyuan Huang Xiangqi Meng Yuxiang Weng Luyuan Zhang Linghao Bu Xiujue Zheng Jinquan Cai Renya Zhan Qun Chen Source Type: research
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy
Biomed Pharmacother. 2023 Jul 15;165:115174. doi: 10.1016/j.biopha.2023.115174. Online ahead of print.ABSTRACTGlioblastoma (GBL) is the most common (60-70% of primary brain tumours) and the most malignant of the glial tumours. Although current therapies remain palliative, they have been proven to prolong overall survival. Within an optimal treatment regimen (incl. surgical resection, radiation therapy, and chemotherapy) temozolomide as the current anti-GBL first-line chemotherapeutic has increased the median overall survival to 14-15 months, and the percentage of patients alive at two years has been reported to rise from 1...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 17, 2023 Category: Drugs & Pharmacology Authors: Aleksandra Krajcer Ewelina Grzywna Joanna Lewandowska- Łańcucka Source Type: research
First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non-Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
JTO Clin Res Rep. 2023 Jun 15;4(7):100536. doi: 10.1016/j.jtocrr.2023.100536. eCollection 2023 Jul.ABSTRACTALK-EML4 fusion-positive lung adenocarcinomas (LUADs) are effectively treated with ALK tyrosine kinase inhibitors, but most patients eventually develop resistance to these drugs owing to ALK-dependent or independent mechanisms. Endothelial to mesenchymal transformation with SCLC development is an ALK-independent mechanism of resistance that has not been previously reported with sequential ALK I1171T mutation while the patient is on treatment for the SCLC. Here, we report the first case of sequential SCLC transformatio...
Source: Cell Research - July 17, 2023 Category: Cytology Authors: Umair Majeed Shenduo Li Karan Seegobin Aziza Nassar Rami Manochakian Yujie Zhao Yanyan Lou Source Type: research
Strategies increasing the effectiveness of temozolomide at various levels of anti-GBL therapy
Biomed Pharmacother. 2023 Jul 15;165:115174. doi: 10.1016/j.biopha.2023.115174. Online ahead of print.ABSTRACTGlioblastoma (GBL) is the most common (60-70% of primary brain tumours) and the most malignant of the glial tumours. Although current therapies remain palliative, they have been proven to prolong overall survival. Within an optimal treatment regimen (incl. surgical resection, radiation therapy, and chemotherapy) temozolomide as the current anti-GBL first-line chemotherapeutic has increased the median overall survival to 14-15 months, and the percentage of patients alive at two years has been reported to rise from 1...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 17, 2023 Category: Drugs & Pharmacology Authors: Aleksandra Krajcer Ewelina Grzywna Joanna Lewandowska- Łańcucka Source Type: research
The treatment of aggressive prolactinomas with everolimus
CONCLUSION: Everolimus is an active agent in the treatment of prolactinomas that warrants further investigation.PMID:37428396 | DOI:10.1007/s11102-023-01340-5
Source: Cancer Control - July 10, 2023 Category: Cancer & Oncology Authors: Andrew L Lin Eliza B Geer Nupur Lala Gabrielle Page-Wilson Rajiv Magge Robert J Young Viviane Tabar Source Type: research
Circ < em > TTLL13 < /em > Promotes TMZ Resistance in Glioma via Modulating < em > OLR1 < /em > -Mediated Activation of the Wnt/ β-Catenin Pathway
This study offers an insight into the efficacy improvement of TMZ for glioma treatment.PMID:37427890 | DOI:10.1080/10985549.2023.2210032
Source: Mol Biol Cell - July 10, 2023 Category: Molecular Biology Authors: Jun Li Junfeng Ma Shan Huang Jun Li Liang Zhou Jiahua Sun Lin Chen Source Type: research
